New peer-reviewed, scientific study shows Vyleesi enhances sexual brain processing in premenopausal women with HSDD. Click here to learn more ›

October 2022

Palatin Announces $10 Million Registered Direct Offering

 Oct 31, 2022, 09:30 ET  CRANBURY, N.J., Oct. 31, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and …

Palatin Announces $10 Million Registered Direct Offering Read More »

Palatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting

 Oct 24, 2022, 17:32 ET  Preclinical data shows efficacy in animal models of ulcerative colitis Human pharmacokinetic data show oral formulation releases PL8177 in colon CRANBURY, N.J., Oct. 24, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor …

Palatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting Read More »

First Patient Enrolled in Palatin’s Phase 2 study of PL8177 in Ulcerative Colitis Trial

 Oct 20, 2022, 07:30 ET  Oral PL8177 may provide an effective, safe, and tolerable treatment option for ulcerative colitis patients prior to being treated with immunosuppressive therapies, which have significant safety and tolerability concerns Primary endpoint is the Mayo Endoscopic Subscore, which evaluates the level of disease in the colon mucosa Interim data currently expected …

First Patient Enrolled in Palatin’s Phase 2 study of PL8177 in Ulcerative Colitis Trial Read More »

Palatin Announces Publication of Vyleesi® (bremelanotide) fMRI Study in Women with Hypoactive Sexual Desire Disorder (HSDD)

 Oct 17, 2022, 07:30 ET  Peer-reviewed paper presents notable mechanism of action findings Bremelanotide significantly increased sexual desire for up to 24 hours post administration CRANBURY, NJ, Oct. 17, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor …

Palatin Announces Publication of Vyleesi® (bremelanotide) fMRI Study in Women with Hypoactive Sexual Desire Disorder (HSDD) Read More »

Palatin Announces Preliminary First Quarter Fiscal 2023 Vyleesi® Product Sales Results

 Oct 13, 2022, 07:30 ET  Net product revenue for prescriptions dispensed increased 20% Prescriptions dispensed increased 17%, over prior quarter Refills accounted for over 50% of prescriptions dispensed CRANBURY, N.J., Oct. 13, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of …

Palatin Announces Preliminary First Quarter Fiscal 2023 Vyleesi® Product Sales Results Read More »

Scroll to Top